comparemela.com

Latest Breaking News On - Blais university - Page 2 : comparemela.com

Caresyntax and UMass Medical School Program on Surgical Safety Selected for 2020 Massachusetts Digital Health Sandbox Network

Caresyntax and UMass Medical School Program on Surgical Safety Selected for 2020 Massachusetts Digital Health Sandbox Network Will identify predictive indicators of surgical risk, develop simulation programs to remotely train residents News provided by Share this article Share this article BOSTON, Jan. 19, 2021 /PRNewswire/  Caresyntax, a pioneer in surgical automation, analytics, and AI software and technologies, today announced that it was selected to join the Massachusetts Digital Health Sandbox Network as part of a joint project with the University of Massachusetts Medical School (UMMS) to install a digital platform in operating rooms that can enable video-based assessments of a surgeon s technical performance.

Atalanta Therapeutics founded by UMass Medical School and three faculty members

Atalanta Therapeutics founded by UMass Medical School and three faculty members Biotech launches with $110 million to pioneer RNA therapeutics for neurodegenerative diseases By Mark L. Shelton January 12, 2021 Atalanta Therapeutics, a biotech founded by UMass Medical School and three faculty research scientists to pioneer treatment options for neurodegenerative diseases, has launched with financing by venture capital fund F-Prime Capital and strategic collaborations with Biogen and Genentech. Atalanta’s technology, called branched siRNA and licensed from UMass Medical School, is based on more than 30 years of research at the Medical School in the field of RNA biology and its clinical applications. Branched siRNA is a novel oligonucleotide architecture that has shown potent ability to silence gene expression in the central nervous system and can be applied across multiple neurodegenerative diseases.

Atalanta Therapeutics Launches With $110 Million to Pioneer RNAi Therapeutics for Neurodegenerative Diseases

Inside the new mRNA vaccines for COVID-19

Inside the new mRNA vaccines for COVID-19 How the Pfizer and Moderna vaccines work to prime the human immune system to fight SARS-CoV-2 By Jim Fessenden December 18, 2020 Health care workers across the nation this week are the first Americans to receive the new mRNA vaccine by Pfizer/BioNTech to protect against COVID-19, and the Moderna vaccine appears soon to follow, with emergency approval by the Food and Drug Administration possible any day. The new mRNA vaccines are the first of their kind and researchers at UMass Medical School are among the leading RNA biologists in the world. The Medical School is home to the

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.